Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression

Gynecologic Oncology

Volumn 125, Issue 1, 2012, Pages 231-236

  Carrara, Luisa ^b   Guzzo, Federica ^c   Roque, Dana M ^a   Bellone, Stefania ^a   Emiliano, Cocco ^a   Sartori, Enrico ^b   Pecorelli, Sergio ^b   Schwartz, Peter E ^a   Rutherford, Thomas J ^a   Santin, Alessandro D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Endometrial neoplasms; HER 2 neu; Paclitaxel; Patupilone; Uterine serous tumors

Indexed keywords

BETA TUBULIN; EPOTHILONE B; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CARCINOSARCOMA; CELL ASSAY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; GENETIC MARKER; GROWTH RATE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; UTERUS CANCER;

AGED; ANTINEOPLASTIC AGENTS; CARCINOSARCOMA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; EPOTHILONES; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; REAL-TIME POLYMERASE CHAIN REACTION; TUBULIN; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS;

EID: 84858340202     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.12.446     Document Type: Article

References (29)

1. G. Garg, J.P. Shah, S. Kumar, C.S. Bryant, A. Munkarah, and R.T. Morris Ovarian and uterine carcinosarcomas: a comparative analysis of prognostic variables and survival outcomes Int J Gynecol Cancer 20 5 2010 888 894
2. T. Le, G.V. Krepart, R.J. Lotocki, and M.S. Heywood Malignant mixed mesodermal ovarian tumor treatment and prognosis: a 20-year experience Gynecol Oncol 65 2 1997 237 240 (Pubitemid 27216934)
3. D.R. Crotzer, J.K. Wolf, J.B. Gano, D.M. Gershenson, and C. Levenback A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary Gynecol Oncol 105 2 2007 399 403 (Pubitemid 46590332)
4. L.R. Duska, A. Garrett, G.H. Eltabbakh, E. Oliva, R. Penson, and A.F. Fuller Paclitaxel and platinum chemotherapy for malignant mixed mullerian tumors of the ovary Gynecol Oncol 85 3 2002 459 463 (Pubitemid 34651885)
5. A.L. Leiser, D.S. Chi, N.M. Ishill, and W.P. Tew Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience Gynecol Oncol 105 3 2007 657 661 (Pubitemid 46734188)
6. D. Gupta, R.L. Owers, M. Kim, D.Y. Kuo, G.S. Huang, and S. Shahabi A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers Gynecol Oncol 113 3 2009 327 330
7. B.E. Miller, J.A. Blessing, F.B. Stehman, M.S. Shahin, S.D. Yamada, and A.A. Secord A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study Gynecol Oncol 118 2 2010 139 144
8. D.M. Bollag, P.A. McQueney, J. Zhu, O. Hensens, L. Koupal, and J. Liesch Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action Cancer Res 55 11 1995 2325 2333
9. K.H. Altmann Recent developments in the chemical biology of epothilones Curr Pharm Des 11 13 2005 1595 1613
10. L.B. Michaud The epothilones: how pharmacology relates to clinical utility Ann Pharmacother 43 7 2009 1294 1309
11. W.W. Ten Bokkel Huinink, J. Sufliarsky, W.M. Smit, S. Spanik, M. Wagnerova, and H.W. Hirte Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study J Clin Oncol 27 19 2009 3097 3103
12. A. Banerjee Increased levels of tyrosinated alpha-, beta(III)-, and beta(IV)-tubulin isotypes in paclitaxel-resistant MCF-7 breast cancer cells Biochem Biophys Res Commun 293 1 2002 598 601 (Pubitemid 34694251)
13. E. Draberova, Z. Lukas, D. Ivanyi, V. Viklicky, and P. Draber Expression of class III beta-tubulin in normal and neoplastic human tissues Histochem Cell Biol 109 3 1998 231 239 (Pubitemid 28114287)
14. G. Carles, D. Braguer, C. Dumontet, V. Bourgarel, A. Goncalves, and M. Sarrazin Differentiation of human colon cancer cells changes the expression of beta-tubulin isotypes and MAPs Br J Cancer 80 8 1999 1162 1168 (Pubitemid 29264075)
15. C. Stengel, S.P. Newman, M.P. Leese, B.V. Potter, M.J. Reed, and A. Purohit Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents Br J Cancer 102 2 2010 316 324
16. S. Terry, G. Ploussard, Y. Allory, N. Nicolaiew, F. Boissiere-Michot, and P. Maille Increased expression of class III beta-tubulin in castration-resistant human prostate cancer Br J Cancer 101 6 2009 951 956
17. P. Seve, T. Reiman, and C. Dumontet The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer Lung Cancer 67 2 2010 136 143
18. P. Seve, S. Isaac, O. Tredan, P.J. Souquet, Y. Pacheco, and M. Perol Expression of class III beta-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy Clin Cancer Res 11 15 2005 5481 5486 (Pubitemid 41060824)
19. G. Ferrandina, G.F. Zannoni, E. Martinelli, A. Paglia, V. Gallotta, and S. Mozzetti Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients Clin Cancer Res 12 9 2006 2774 2779
20. T. Umezu, K. Shibata, H. Kajiyama, M. Terauchi, K. Ino, and A. Nawa Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin Int J Gynecol Pathol 27 2 2008 207 212 (Pubitemid 351450662)
21. S. Hasegawa, Y. Miyoshi, C. Egawa, M. Ishitobi, T. Taguchi, and Y. Tamaki Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers Clin Cancer Res 9 8 2003 2992 2997 (Pubitemid 36993258)
22. S. Mozzetti, R. Iantomasi, I. De Maria, S. Prislei, M. Mariani, and A. Camperchioli Molecular mechanisms of patupilone resistance Cancer Res 68 24 2008 10197 10204
23. Homesley HD, Filiaci V, Markman M, Bitterman P, Eaton L, Kilgore LC, Monk BJ, and Ueland FR. Phase III Trial of Ifosfamide With or Without Paclitaxel in Advanced Uterine Carcinosarcoma: A Gynecologic Oncology Group Study. 2007; J Clin Oncol 25:526-531.
24. K.L. Cheng, T. Bradley, and D.R. Budman Novel microtubule-targeting agents - the epothilones Biologics 2 4 2008 789 811
25. T. Chen, A. Molina, S. Moore, S. Goel, K. Desai, and A. Hamilton Epothilone B analog (BMS-247550) at the recommended phase II dose (RPTD) in patients with gyneologic and breast cancers J Clin Oncol 22(Suppl) 2004 155s (Abstr 2115)
26. K. De Geest, J.A. Blessing, R.T. Morris, S.D. Yamada, B.J. Monk, and S.L. Zweizig Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study J Clin Oncol 28 1 2010 149 153
27. D.S. Dizon, J.A. Blessing, D.S. McMeekin, S.K. Sharma, P. Disilvestro, and R.D. Alvarez Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P J Clin Oncol 27 19 2009 3104 3108
28. R. Bernards It's diagnostics, stupid Cell 141 1 2010 Apr 2 13 17
29. D. Paik, E. Cocco, S. Bellone, F. Casagrande, M. Bellone, and E.E. Siegel Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro Gynecol Oncol 119 1 2010 140 145